When used in children helps prevent the appearance of  rash, protects against the action of urine and other irritating substances and soothes irritated skin. Reduces Moisture and exudation, reduces local inflammation and irritation phenomena. Symptomatic and the protective effect of the drug is determined by the zinc oxide. Zinc oxide …

Possible strengthening of toxicity when ganciclovir concomitantly with other drugs having myelosuppressive effect of violating or renal function (such as dapsone, pentamidine, flucytosine, vincristine, vinblastiin, adriamycin, amphotericin B, nucleoside analogues and hydroxyurea). Consequently, this primobolan results medication should be administered concurrently with ganciclovir only if the potential benefits outweigh the potential …

In case of overdose, in some cases, no adverse events did not occur. The majority of patients had one or more of the following adverse events: Haematological toxicity: pancytopenia, myelosuppression, bone marrow aplasia, leucopenia, neutropenia, granulocytopenia. Hepatotoxicity: hepatitis, abnormal liver function. Renal rimobolan dosage toxicity: the growth of haematuria in a …

A complete description of the safety profile of intravenous ganciclovir are given below the corresponding adverse events identified with greater frequency, with oral ganciclovir in primobolan depot patients or after organ transplantation, regardless of their severity and causal relationship with the drug. Some adverse events with oral ganciclovir may be …

The clinical adverse events that occurred in 2% of patients intravenously received ganciclovir, regardless of causal relationship to medication and severity: the blood methenolone system and lymphatic system:neutropenia, anemia, thrombocytopenia, leukopenia, lymphadenopathy, by of the digestive system: diarrhea, abdominal pain, dysphagia, esophageal candidiasis, the body as a whole: fever, candidiasis, an …